2024
Report from the World Health Organization’s immunization and vaccines related implementation research advisory committee (IVIR-AC) meeting, Geneva, 11–13 September 2023
Lambach P, Orenstein W, Silal S, Sbarra A, Koh M, Aggarwal R, Farooqui H, Flasche S, Hogan A, Kim S, Leask J, Luz P, Lyimo D, Moss W, Pitzer V, Wang X, Wu J. Report from the World Health Organization’s immunization and vaccines related implementation research advisory committee (IVIR-AC) meeting, Geneva, 11–13 September 2023. Vaccine 2024, 42: 1424-1434. PMID: 38326131, PMCID: PMC10953699, DOI: 10.1016/j.vaccine.2024.02.014.Peer-Reviewed Original Research
2023
Bacterial production of recombinant contraceptive vaccine antigen from CatSper displayed on a human papilloma virus-like particle
Nand K, Jordan T, Yuan X, Basore D, Zagorevski D, Clarke C, Werner G, Hwang J, Wang H, Chung J, McKenna A, Jarvis M, Singh G, Bystroff C. Bacterial production of recombinant contraceptive vaccine antigen from CatSper displayed on a human papilloma virus-like particle. Vaccine 2023, 41: 6791-6801. PMID: 37833124, DOI: 10.1016/j.vaccine.2023.09.044.Peer-Reviewed Original ResearchConceptsVirus-like particlesSperm hyperactivated motilityHuman papilloma virusInclusion bodiesLong-acting protectionCalcium ion channelsNon-hormonal interventionsContraceptive efficacyHyperactivated motilityPapilloma virusPrincipal pieceSperm tailContraceptive vaccineBALB/c miceHypervariable regionCatSperVaccine antigensBacterial productionVaccine candidatesIon channelsIn vitroVaccinePregnancyRecombinant vaccineExtracellular loop
2022
Cancer risk factors and cancer in transgender versus cisgender people: Real-world data from a tertiary health care institution.
Alpert A, Sayegh S, Strawderman M, Cunliffe S, Cupertino A, Cerulli C, Griggs J. Cancer risk factors and cancer in transgender versus cisgender people: Real-world data from a tertiary health care institution. Journal Of Clinical Oncology 2022, 40: 6538-6538. DOI: 10.1200/jco.2022.40.16_suppl.6538.Peer-Reviewed Original ResearchCancer risk factorsElectronic health recordsBody mass indexPrevalence of cancerHuman immunodeficiency virusCisgender peopleRisk factorsElectronic health record fieldsInstitutional electronic health recordsAssessed body mass indexTransgender peopleTertiary health care institutionHuman papilloma virusRates of smokingHealth care institutionsPremalignant lesionsGender identity dataYears of follow-upPrevalence of premalignant lesionsTobacco cessationHealth recordsStructural stigmaChi-square testSmoking statusTransmission of human immunodeficiency virus
2021
Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer
Xiao C, Miller AH, Peng G, Levine ME, Conneely KN, Zhao H, Eldridge RC, Wommack EC, Jeon S, Higgins KA, Shin DM, Saba NF, Smith AK, Burtness B, Park HS, Irwin ML, Ferrucci LM, Ulrich B, Qian DC, Beitler JJ, Bruner DW. Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 157-167. PMID: 33882281, PMCID: PMC8802868, DOI: 10.1016/j.ijrobp.2021.04.002.Peer-Reviewed Original ResearchConceptsProgression-free survivalBody mass indexQuality of lifeHigher epigenetic age accelerationTreatment-related symptomsOverall survivalEpigenetic age accelerationRadiation therapyRisk factorsClinical characteristicsNeck cancerAge accelerationWorse overall survivalHuman papilloma virusFaster biological agingAdverse eventsDistant metastasisLifestyle factorsMass indexCancer outcomesBlood biomarkersPapilloma virusFunctional assessmentHigher HRPatientsNon-HPV-Associated Cervical Neoplasia
Quddus M, Ou J, Hui P. Non-HPV-Associated Cervical Neoplasia. Practical Anatomic Pathology 2021, 95-111. DOI: 10.1007/978-3-030-68608-6_4.Peer-Reviewed Original ResearchCervical adenocarcinomaHigh-risk human papilloma virusDaily practiceGestational trophoblastic tumorsHuman papilloma virusSquamous cell carcinomaUterine cervical carcinomaBiopsy/resectionTrophoblastic tumorCervical neoplasiaCell carcinomaCervical carcinomaDiagnostic challengeMetastatic tumorsPapilloma virusMalignant melanomaBenign lesionsTumorsHrHPVAdenocarcinomaCarcinomaSignificant percentagePathologistsHPVResection
2018
KDM5 histone demethylases repress immune response via suppression of STING
Wu L, Cao J, Cai WL, Lang SM, Horton JR, Jansen DJ, Liu ZZ, Chen JF, Zhang M, Mott BT, Pohida K, Rai G, Kales SC, Henderson MJ, Hu X, Jadhav A, Maloney DJ, Simeonov A, Zhu S, Iwasaki A, Hall MD, Cheng X, Shadel GS, Yan Q. KDM5 histone demethylases repress immune response via suppression of STING. PLOS Biology 2018, 16: e2006134. PMID: 30080846, PMCID: PMC6095604, DOI: 10.1371/journal.pbio.2006134.Peer-Reviewed Original ResearchConceptsImmune responseSTING expressionCyclic GMP-AMP synthase stimulatorSuppression of STINGCancer cellsCancer immunotherapy agentsHuman papilloma virusAdaptive immune responsesMultiple clinical trialsExpression of STINGBreast cancer cellsInnate immune defenseRobust interferon responseMultiple cancer typesIntratumoral CD8Immunotherapy agentsAnticancer immunotherapyPatient survivalNeck cancerPapilloma virusClinical trialsT cellsSTING agonistsKDM5 histonePositive headSignificance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer
Ng S, Johnson J, Gunn G, Rosenthal D, Skinner H, Phan J, Frank S, Morrison W, Sturgis E, Mott F, Williams M, Fuller C, Garden A. Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: 1029-1035. PMID: 29960060, PMCID: PMC9620951, DOI: 10.1016/j.ijrobp.2018.06.031.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell carcinomaComplete metabolic responseDisease-free survivalOverall survival rateSquamous cell carcinomaCell carcinomaTomography scanSurvival rateHPV-positive oropharyngeal cancerCommon primary siteHPV/p16Posttreatment PET imagingPosttreatment PET scansKaplan-Meier methodSubgroup of patientsBase of tongueGroup of patientsHuman papilloma virusDevelopment of recurrencePET/CT imagingMetabolic responseOptimal surveillance strategyPositron emission tomographyLonger life expectancyEleven patientsSex differences in patients with high risk HPV-associated and HPV negative oropharyngeal and oral cavity squamous cell carcinomas
Li H, Park HS, Osborn HA, Judson BL. Sex differences in patients with high risk HPV-associated and HPV negative oropharyngeal and oral cavity squamous cell carcinomas. Cancers Of The Head & Neck 2018, 3: 4. PMID: 31093357, PMCID: PMC6460664, DOI: 10.1186/s41199-018-0031-y.Peer-Reviewed Original ResearchSquamous cell carcinomaNational Cancer DatabaseOverall survivalOral cavityHPV cancersCell carcinomaHPV-negative squamous cell carcinomaOral cavity squamous cell carcinomaOP SCCHigh-risk human papillomavirusImproved overall survivalRetrospective cohort studyHigh-risk HPVDistinct clinical entityHuman papilloma virusLog-rank testKaplan-Meier estimatesOral cavity sitesChi-square testHPV carcinogenesisWorse OSCohort studyHPV statusRisk HPVClinical entityIncidence of radiographically occult nodal metastases in HPV+ oropharyngeal carcinoma: Implications for reducing elective nodal coverage
Loganadane G, Kelly JR, Lee NC, Kann BH, Mahajan A, Hansen JE, Belkacémi Y, Yarbrough W, Husain ZA. Incidence of radiographically occult nodal metastases in HPV+ oropharyngeal carcinoma: Implications for reducing elective nodal coverage. Practical Radiation Oncology 2018, 8: 397-403. PMID: 29730282, DOI: 10.1016/j.prro.2018.03.009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Squamous CellFemaleFollow-Up StudiesHumansImage Processing, Computer-AssistedLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOropharyngeal NeoplasmsPapillomaviridaePapillomavirus InfectionsPositron Emission Tomography Computed TomographyPrognosisRadiotherapy DosageRadiotherapy Planning, Computer-AssistedRadiotherapy, Intensity-ModulatedRetrospective StudiesConceptsRadiation field designPreoperative imagingPathologic involvementN stageOropharyngeal squamous cell carcinomaElective nodal coverageLevel II diseasePercent of patientsPositive lymph nodesOccult nodal metastasisClinical N stageRadiation therapy doseRecords of patientsNodal levelPathologic N stageSquamous cell carcinomaHuman papilloma virusTreatment deescalationNeoadjuvant therapyNodal diseaseNeck dissectionNodal involvementOropharyngeal carcinomaProspective trialSystemic agents
2017
Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer
Skinner HD, Giri U, Yang LP, Kumar M, Liu Y, Story MD, Pickering CR, Byers LA, Williams MD, Wang J, Shen L, Yoo SY, Fan YH, Molkentine DP, Beadle BM, Meyn RE, Myers JN, Heymach JV. Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. Clinical Cancer Research 2017, 23: 2713-2722. PMID: 28476872, PMCID: PMC5457365, DOI: 10.1158/1078-0432.ccr-16-2586.Peer-Reviewed Original ResearchMeSH KeywordsAgedAxl Receptor Tyrosine KinaseB7-H1 AntigenBiomarkers, TumorCarcinoma, Squamous CellCell Line, TumorFemaleGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedPapillomaviridaePhosphatidylinositol 3-KinasesProteomicsProto-Oncogene ProteinsRadiation ToleranceReceptor Protein-Tyrosine KinasesRNA, MessengerSignal TransductionConceptsPD-L1HPV-negative HNSCC tumorsNeck squamous cell carcinomaCell linesHPV-negative HNSCC cell linesLocal failureLocal treatment failurePD-L1 axisPD-L1 expressionTumor-infiltrating lymphocytesSquamous cell carcinomaHuman papilloma virusLow expression groupActivation of AxlHNSCC cell linesClin Cancer ResNegative cell linesTreatment failureCell carcinomaPapilloma virusHNSCC tumorsExpression groupMultivariate analysisMRNA expression analysisPI3-kinase
2016
Selective antitumor activity of roscovitine in head and neck cancer
Gary C, Hajek M, Biktasova A, Bellinger G, Yarbrough WG, Issaeva N. Selective antitumor activity of roscovitine in head and neck cancer. Oncotarget 2016, 7: 38598-38611. PMID: 27233076, PMCID: PMC5122414, DOI: 10.18632/oncotarget.9560.Peer-Reviewed Original ResearchConceptsNeck cancerSide effectsGrowth of HPVHPV-negative tissuesHPV-positive headCancer cellsHuman papilloma virusTargeted therapeutic optionsDetectable side effectsNeck cancer cellsNormal cellsDNA damageRoscovitine administrationHPV positivityCyclin-dependent kinase inhibitorTherapeutic optionsUnwanted side effectsPapilloma virusCdk-7Xenografted tumorsP53-dependent cell deathSignificant DNA damageSelective antitumor activitySensitivity of cellsKinase inhibitorsAnal cancer and intraepithelial neoplasia screening: A review.
Leeds IL, Fang SH. Anal cancer and intraepithelial neoplasia screening: A review. World Journal Of Gastrointestinal Surgery 2016, 8: 41-51. PMID: 26843912, PMCID: PMC4724586, DOI: 10.4240/wjgs.v8.i1.41.Peer-Reviewed Original ResearchAnal cancerRoutine screeningIntraepithelial neoplasiaCervical cancerAnal cancer preventionInvasive anal cancerSimilar tumor biologyAnal intraepithelial neoplasiaCancer screening recommendationsRisk stratification strategiesHuman papilloma virusAnorectal examPapanicolaou (Pap) testingScreening recommendationsPapilloma virusClinical rationalePrecursor lesionsCancer preventionScreening modalityPotential screening modalitiesEarly diagnosisLow prevalenceGeneral populationDisease processTumor biology
2015
Cost effectiveness of transoral robotic surgery for the treatment of oropharyngeal squamous cell carcinoma: a systematic review
Aaronson N, Neubauer P, Judson B. Cost effectiveness of transoral robotic surgery for the treatment of oropharyngeal squamous cell carcinoma: a systematic review. Robotic Surgery Research And Reviews 2015, 2: 59-63. DOI: 10.2147/rsrr.s64869.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaSquamous cell carcinomaTransoral robotic surgeryCell carcinomaTreatment of OPSCCSystematic reviewDa Vinci robotic surgical systemRobotic surgeryHigh functional morbidityNon-surgical treatmentHuman papilloma virusCost of treatmentDa Vinci robotSubsequent FDA approvalAdjuvant treatmentHospital stayLonger hospitalizationRobotic surgical systemOropharyngeal cancerUnknown primaryCase seriesGastrostomy tubeOpen surgeryTransoral resectionFunctional morbidity
2014
E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).
Cmelak A, Li S, Marur S, Zhao W, Westra W, Chung C, Gillison M, Gilbert J, Bauman J, Wagner L, Ferris R, Trevarthen D, Colevas A, Jahagirdar B, Burtness B. E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). Journal Of Clinical Oncology 2014, 32: lba6006-lba6006. DOI: 10.1200/jco.2014.32.18_suppl.lba6006.Peer-Reviewed Original ResearchClinical complete responseOropharyngeal squamous carcinomaLate grade 3 toxicityPost-treatment neck dissectionStage III/IVAHigh tumor control ratesGrade 3 toxicityWeek x 3Tumor control rateHuman papilloma virusLate toxicityPrimary endpointCurrent smokersComplete responseNeck dissectionNodal stageSquamous carcinomaControl ratePapilloma virusC-IMRTT1-3Weekly schedulePFSInvolved nodesDoseE1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).
Cmelak A, Li S, Marur S, Zhao W, Westra W, Chung C, Gillison M, Gilbert J, Bauman J, Wagner L, Ferris R, Trevarthen D, Colevas A, Jahagirdar B, Burtness B. E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). Journal Of Clinical Oncology 2014, 32: lba6006-lba6006. DOI: 10.1200/jco.2014.32.15_suppl.lba6006.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinoma treatment
Marur S, Burtness B. Oropharyngeal squamous cell carcinoma treatment. Current Opinion In Oncology 2014, 26: 252-258. PMID: 24626127, PMCID: PMC5813288, DOI: 10.1097/cco.0000000000000072.Peer-Reviewed Original ResearchConceptsHigh-risk human papilloma virusOropharyngeal squamous cell carcinomaHPV-unrelated cancersSquamous cell carcinomaNodal stageCell carcinomaTumor stageSquamous cell carcinoma treatmentHPV-unrelated tumorsAdvanced nodal stageRisk of deathCurrent treatment paradigmsHuman papilloma virusParaffin-embedded tissue blocksImportant causative factorAdvanced nodalDistant diseaseHPV statusCurative therapyFavorable prognosisOropharyngeal cancerRetrospective studyPapilloma virusTreatment paradigmRisk groupsTransoral Robotic Surgery: A Population‐Level Analysis
Chen MM, Roman SA, Kraus DH, Sosa JA, Judson BL. Transoral Robotic Surgery: A Population‐Level Analysis. Otolaryngology 2014, 150: 968-975. PMID: 24618503, DOI: 10.1177/0194599814525747.Peer-Reviewed Original ResearchConceptsTransoral robotic surgeryNational Cancer DatabaseUnplanned readmissionPositive marginsNonrobotic surgeryOropharyngeal cancerTORS patientsMargin statusCancer DatabaseUse of TORSLower ratesCommunity cancer centerHigh-volume centersLow-volume centersHuman papilloma virusRetrospective database reviewOutcomes of interestAdjuvant chemoradiationAdjuvant therapyHPV positivityPathologic characteristicsPositive tumorsCancer CenterPapilloma virusDatabase review
2013
Public awareness of the HPV vaccine: A national population-based study.
Shrader A, Niccolai L, Mayne S, DiMaio D, Chagpar A. Public awareness of the HPV vaccine: A national population-based study. Journal Of Clinical Oncology 2013, 31: 1574-1574. DOI: 10.1200/jco.2013.31.15_suppl.1574.Peer-Reviewed Original ResearchHPV vaccineHuman papilloma virusNational population-based studyNational Health Interview SurveyPublic health educational programsHPV vaccine awarenessPopulation-based studyHealth Interview SurveyNumber of malignanciesHealth educational programsVaccine awarenessPapilloma virusNational guidelinesUS populationMultivariate analysisVaccineUninsured populationInterview SurveyMore womenSignificant predictorsWomenOlder counterpartsYounger cohortsMenPublic awarenessE 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC).
Marur S, Li S, Cmelak A, Gillison M, Ferris R, Bauman J, Zhao W, Westra W, Chung C, Wagner L, Trevarthen D, Jahagirdar B, Colevas A, Burtness B. E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC). Journal Of Clinical Oncology 2013, 31: 6005-6005. DOI: 10.1200/jco.2013.31.15_suppl.6005.Peer-Reviewed Original ResearchClinical complete responseGrade 3/4 toxicitiesInduction chemotherapyLow doseBetter overall clinical responseCycles of ICPost-treatment neck dissectionResectable squamous cell carcinomaStage III/IVAOverall clinical responseWeek x 3Phase II trialSquamous cell carcinomaHuman papilloma virusPost-baseline measurementRadiation dose reductionEligible ptsHPV-OPSCCYear PFSOPSCC patientsPrimary endpointSecondary endpointsClinical responseCurrent smokersII trial
2008
Circumscribed palmar hypokeratosis: two cases and a review of the literature
Barry CI, Glusac EJ, Kashgarian M, Gwin K, McNiff JM. Circumscribed palmar hypokeratosis: two cases and a review of the literature. Journal Of Cutaneous Pathology 2008, 35: 484-487. PMID: 18399810, DOI: 10.1111/j.1600-0560.2007.00835.x.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply